The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients With Coronary Artery Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1600 participants.

Also called NCT01508663

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,600 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01508663
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
Not reported
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01508663. Randomized; no masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2014-02 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients With Coronary Artery Disease
Acronym
BRAVE
Intervention (Device)
Everolimus Eluting Stent or Zotalolimus Eluting Stent
Intervention (Drug)
ARB, CCB, ACE-inhibitor (ACE inhibitor), statin, Nitrate, Antiplate etc.
Lead sponsor
Yonsei University (class: other)

Record details

Record id
cardio:ct-nct01508663
Content hash
a9ae07c11610cfc1d3ee294ec7ee4579513703933104b741339c08c2bd953222